328 related articles for article (PubMed ID: 17028666)
1. Tocilizumab: blockade of interleukin-6 signaling pathway as a therapeutic strategy for inflammatory disorders.
Paul-Pletzer K
Drugs Today (Barc); 2006 Sep; 42(9):559-76. PubMed ID: 17028666
[TBL] [Abstract][Full Text] [Related]
2. Immunotherapeutic implication of IL-6 blockade.
Tanaka T; Kishimoto T
Immunotherapy; 2012 Jan; 4(1):87-105. PubMed ID: 22150003
[TBL] [Abstract][Full Text] [Related]
3. Clinical studies in patients with Castleman's disease, Crohn's disease, and rheumatoid arthritis in Japan.
Nishimoto N
Clin Rev Allergy Immunol; 2005 Jun; 28(3):221-30. PubMed ID: 16129906
[TBL] [Abstract][Full Text] [Related]
4. Anti-interleukin-6 receptor antibody therapy in rheumatic diseases.
Nakahara H; Nishimoto N
Endocr Metab Immune Disord Drug Targets; 2006 Dec; 6(4):373-81. PubMed ID: 17214583
[TBL] [Abstract][Full Text] [Related]
5. [Anti-IL-6 receptor antibody].
Nishimoto N
Nihon Rinsho; 2005 May; 63 Suppl 5():723-7. PubMed ID: 15954436
[No Abstract] [Full Text] [Related]
6. [Humanized anti-human IL-6 receptor antibody, tocilizumab].
Nishimoto N
Nihon Rinsho; 2007 Jul; 65(7):1218-25. PubMed ID: 17642235
[TBL] [Abstract][Full Text] [Related]
7. [IL-6 blockade therapy for inflammatory diseases: current perspectives and future directions].
Tanaka T
Nihon Rinsho Meneki Gakkai Kaishi; 2015; 38(6):433-42. PubMed ID: 27118330
[TBL] [Abstract][Full Text] [Related]
8. Humanized antihuman IL-6 receptor antibody, tocilizumab.
Nishimoto N; Kishimoto T
Handb Exp Pharmacol; 2008; (181):151-60. PubMed ID: 18071945
[TBL] [Abstract][Full Text] [Related]
9. Clinical value of blocking IL-6 receptor.
Mima T; Nishimoto N
Curr Opin Rheumatol; 2009 May; 21(3):224-30. PubMed ID: 19365268
[TBL] [Abstract][Full Text] [Related]
10. Inhibition of IL-6 for the treatment of inflammatory diseases.
Nishimoto N; Kishimoto T
Curr Opin Pharmacol; 2004 Aug; 4(4):386-91. PubMed ID: 15251133
[TBL] [Abstract][Full Text] [Related]
11. A new era for the treatment of inflammatory autoimmune diseases by interleukin-6 blockade strategy.
Tanaka T; Narazaki M; Ogata A; Kishimoto T
Semin Immunol; 2014 Feb; 26(1):88-96. PubMed ID: 24594001
[TBL] [Abstract][Full Text] [Related]
12. Anti-interleukin-6 receptor antibody treatment in inflammatory autoimmune diseases.
Ding C; Jones G
Rev Recent Clin Trials; 2006 Sep; 1(3):193-200. PubMed ID: 18473972
[TBL] [Abstract][Full Text] [Related]
13. Interleukin 6: from bench to bedside.
Nishimoto N; Kishimoto T
Nat Clin Pract Rheumatol; 2006 Nov; 2(11):619-26. PubMed ID: 17075601
[TBL] [Abstract][Full Text] [Related]
14. The value of blocking IL-6 outside of rheumatoid arthritis: current perspective.
Murakami M; Nishimoto N
Curr Opin Rheumatol; 2011 May; 23(3):273-7. PubMed ID: 21427577
[TBL] [Abstract][Full Text] [Related]
15. Spotlight on sirukumab for the treatment of rheumatoid arthritis: the evidence to date.
Lazzerini PE; Capecchi PL; Guidelli GM; Selvi E; Acampa M; Laghi-Pasini F
Drug Des Devel Ther; 2016; 10():3083-3098. PubMed ID: 27713619
[TBL] [Abstract][Full Text] [Related]
16. Is interleukin-6 receptor blockade the Holy Grail for inflammatory diseases?
Febbraio MA; Rose-John S; Pedersen BK
Clin Pharmacol Ther; 2010 Apr; 87(4):396-8. PubMed ID: 20305672
[TBL] [Abstract][Full Text] [Related]
17. Interleukin-6 in rheumatoid arthritis.
Nishimoto N
Curr Opin Rheumatol; 2006 May; 18(3):277-81. PubMed ID: 16582692
[TBL] [Abstract][Full Text] [Related]
18. [Clinical benefits of anti-human IL-6 receptor antibody therapy].
Nishimoto N
Clin Calcium; 2007 Apr; 17(4):562-8. PubMed ID: 17404486
[TBL] [Abstract][Full Text] [Related]
19. Interleukin-6 inhibition and clinical efficacy in rheumatoid arthritis treatment--data from randomized clinical trials.
Kavanaugh A
Bull NYU Hosp Jt Dis; 2007; 65 Suppl 1():S16-20. PubMed ID: 17708740
[TBL] [Abstract][Full Text] [Related]
20. [IL-6 blockade].
Kaneko Y; Takeuchi T
Nihon Rinsho; 2016 Jun; 74(6):963-7. PubMed ID: 27311186
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]